Dianthus Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Dianthus Therapeutics, Inc. filed its 2023 10-K, detailing its financial position and operations.</b>

AI Summary

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed a Annual Report (10-K) with the SEC on March 21, 2024. Dianthus Therapeutics, Inc. filed its 2023 Form 10-K on March 21, 2024. The company's fiscal year ends on December 31st. Dianthus Therapeutics was formerly known as Magenta Therapeutics, Inc., with a name change on November 21, 2016. The company is incorporated in Delaware and headquartered in Cambridge, MA. The filing includes data related to various financial instruments and expenses, such as warrants, stock options, and R&D expenses.

Why It Matters

For investors and stakeholders tracking Dianthus Therapeutics, Inc. /DE/, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Dianthus Therapeutics' financial performance and strategic activities for the fiscal year 2023, crucial for investors to assess the company's health and future prospects. Understanding the details within this filing is essential for stakeholders to evaluate the company's financial health, operational risks, and potential for growth in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — Dianthus Therapeutics, Inc. /DE/ shows moderate risk based on this filing. The company operates in the pharmaceutical industry, which is subject to significant regulatory hurdles, intense competition, and the inherent risks of drug development, as evidenced by the numerous disclosures typical in a 10-K filing for a company in this sector.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Dianthus Therapeutics' current financial standing and future outlook.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reported period)
• 2024-03-21 — Filing Date (Date of submission)
• 2016-11-21 — Name Change Date (Date Dianthus Therapeutics, Inc. was formerly Magenta Therapeutics, Inc.)

Key Players & Entities

• Dianthus Therapeutics, Inc. (company) — Filer name
• Magenta Therapeutics, Inc. (company) — Former company name
• Cambridge, MA (location) — Business address city and state
• Zenas Biopharma Limited (company) — Mentioned in relation to license revenue
• Alloy Therapeutics LLC (company) — Mentioned in financial data context
• Iontas Limited (company) — Mentioned in financial data context

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The pharmaceutical industry is subject to extensive government regulation, which can impact product development, approval, manufacturing, and marketing.
• Market Competition [high — market]: The company faces intense competition from other pharmaceutical and biotechnology companies, which could affect its ability to gain market share.
• Drug Development Risks [high — operational]: The development of new drugs is a lengthy, expensive, and uncertain process, with a high risk of failure at various stages.
• Funding and Liquidity [medium — financial]: The company may require significant additional capital to fund its operations and development activities, and may not be able to secure such funding on favorable terms.

Key Dates

• 2024-03-21: 10-K Filing — Annual report for fiscal year 2023
• 2023-12-31: Fiscal Year End — End of the reporting period
• 2016-11-21: Name Change — Dianthus Therapeutics, Inc. formerly Magenta Therapeutics, Inc.

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value DNTH The Nasdaq Capital M

Filing Documents

• dnth-20231231.htm (10-K) — 2429KB
• dnth-ex3_2.htm (EX-3.2) — 142KB
• dnth-ex4_5.htm (EX-4.5) — 36KB
• dnth-ex10_6.htm (EX-10.6) — 55KB
• dnth-ex10_8.htm (EX-10.8) — 60KB
• dnth-ex10_15.htm (EX-10.15) — 34KB
• dnth-ex10_19.htm (EX-10.19) — 73KB
• dnth-ex10_20.htm (EX-10.20) — 78KB
• dnth-ex10_22.htm (EX-10.22) — 75KB
• dnth-ex21_1.htm (EX-21.1) — 6KB
• dnth-ex23_1.htm (EX-23.1) — 3KB
• dnth-ex31_1.htm (EX-31.1) — 16KB
• dnth-ex31_2.htm (EX-31.2) — 15KB
• dnth-ex32_1.htm (EX-32.1) — 13KB
• dnth-ex97_1.htm (EX-97.1) — 13KB
• img111988015_0.jpg (GRAPHIC) — 8KB
• img113835057_0.jpg (GRAPHIC) — 8KB
• img189559717_0.jpg (GRAPHIC) — 34KB
• img207615533_0.jpg (GRAPHIC) — 261KB
• img207615533_1.jpg (GRAPHIC) — 19KB
• img207615533_2.jpg (GRAPHIC) — 11KB
• img207615533_3.jpg (GRAPHIC) — 33KB
• 0000950170-24-034681.txt (&nbsp;) — 11574KB
• dnth-20231231.xsd (EX-101.SCH) — 1650KB
• dnth-20231231_htm.xml (XML) — 1547KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 32 Item 1B. Unresolved Staff Comments 65 Item 1C. Cybersecurity 65 Item 2.

Properties

Properties 66 Item 3.

Legal Proceedings

Legal Proceedings 66 Item 4. Mine Safety Disclosures 66 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 67 Item 6. [Reserved] 67 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 68 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 81 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 82 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 111 Item 9A.

Controls and Procedures

Controls and Procedures 111 Item 9B. Other Information 112 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 112 PART III Item 10. Directors, Executive Officers and Corporate Governance 113 Item 11.

Executive Compensation

Executive Compensation 113 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 113 Item 13. Certain Relationships and Related Transactions, and Director Independence 113 Item 14. Principal Accountant Fees and Services 113 PART IV Item 15. Exhibits, Financial Statement Schedules 114 Item 16. Form 10-K Summary 116

Signatures

Signatures 117 i Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical fact, included in this Annual Report on Form 10-K are forward-looking statements, including, without limitation, statements concerning our plans, objectives, goals, expectations, hopes, beliefs, intentions, assumptions, projections, estimates or strategies and any underlying assumptions regarding the future, our future results of operations and financial position, including the sufficiency of our existing cash resources to fund our operations for as long as anticipated, our liquidity, capital resources, costs and expenses, capital requirements, commitments and contingencies, the development or commercial potential of DNTH103 or any other product candidate, our anticipated preclinical and clinical drug development activities, in particular with respect to DNTH103, and any timelines, developments or results in connection therewith, the efficacy, safety profile, dosing amount or frequency, method of delivery or other potential therapeutic benefits of DNTH103, the receipt or timing of potential regulatory designations, approvals and commercialization of any product candidates, market size or addressable patient population and other statements, including those included under the sections titled " Risk Factors, " " Business, " " Management's Discussion and Analysis of Financial Condition and Results of Operations " and elsewhere in this Annual Report on Form 10-K. In some cases, you can identify forward-looking statements by terms such as "aim," "may," "might," "will," "would," "shall," "objective," "intend," "target," "should," "could," "can," "expect," "anticipate," "believe," "design," "estimate,

Business

Item 1. Business. Overview We are a clinical-stage biotechnology company. On September 11, 2023, we completed a business combination with Former Dianthus pursuant to which, among other matters, Former Dianthus became as a wholly owned subsidiary of ours (the "Reverse Merger"). In connection with the completion of the Reverse Merger, we changed our name from "Magenta Therapeutics, Inc." to "Dianthus Therapeutics, Inc.," and the business conducted by us became primarily the business conducted by Former Dianthus. We were incorporated as a Delaware corporation in June 2015 and Former Dianthus was incorporated as a Delaware corporation in May 2019. We are focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. We believe our lead novel and proprietary monoclonal antibody product candidate, DNTH103, has the potential to address a broad array of complement-dependent diseases as currently available therapies and those in development leave room for improvements in efficacy, safety, and/or dosing convenience. We have purposefully engineered DNTH103 to selectively bind to only the active form of the C1s complement protein ("C1s") and to exhibit improved potency and an extended half-life. By selectively targeting only the active form of C1s, which drives disease pathology and constitutes only a small fraction of the total protein present in circulation, we aim to reduce the amount of drug required for a therapeutic effect. We intend to deliver our product candidate through a lower dose, less frequent, self-administered, convenient subcutaneous ("S.C.") injection suitable for a pre-filled pen. Our Pipeline-in-a-Product Potential for DNTH103, a Next-Generation Complement Therapeutic * We hold world-wide rights excluding rights to Greater China, which are outlicensed to Zenas BioPharma, Inc. (formerly Zenas BioPharma Limited) ("Zenas BioPharma"). DNTH103 Our most advanced product candidate, D

View Full Filing

View this 10-K filing on SEC EDGAR